Protalix (PLX) AI Stock Analysis

• Market Cap: $174.61M
• Dividend Yield: N/A
• Average Volume (3M): 963.35K
• Price to Earnings (P/E): 29.6
• Beta (1Y): 0.45
• Revenue Growth: 62.79%
• EPS Growth: N/A
• Country: US
• Employees: 213
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 79,732,120
• 10 Day Avg. Volume: 640,214
• 30 Day Avg. Volume: 963,354
• PEG Ratio: -0.70
• Price to Book (P/B): 3.16
• Price to Sales (P/S): 2.55
• P/FCF Ratio: 18.45
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 2.59
• Enterprise Value/Ebitda: 8.74
• 1Y Price Target: $15.00
• Price Target Upside: 584.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: $2.50 ▲(14.16% Upside)

Protalix's overall stock score is driven by strong earnings call insights and positive technical indicators. Financial performance shows improvement, though leverage concerns persist. Valuation remains a moderate risk due to a high P/E ratio.

Positive Factors

Revenue Growth

The significant revenue growth, driven by Elfabrio sales, indicates strong market demand and effective product positioning, enhancing long-term financial stability.

Product Pipeline

Advancement in the PRX-115 pipeline suggests robust R&D capabilities and potential future revenue streams, reinforcing the company's growth prospects.

Partnerships

Strategic partnerships with firms like Chiesi enhance Protalix's market reach and operational capabilities, supporting sustained business growth.

Negative Factors

Leverage Concerns

High leverage can limit financial flexibility and increase risk, potentially impacting the company's ability to invest in growth opportunities.

Increased R&D Expenses

While essential for innovation, rising R&D costs can pressure margins and cash flow, affecting short-term financial performance.

Sales Decline in Key Markets

Declining sales in significant markets like Brazil and Pfizer partnerships could hinder revenue growth and market expansion efforts.

Protalix Business Overview & Revenue Model

Company Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

How the Company Makes Money

Protalix generates revenue primarily through the sale of its pharmaceutical products, particularly Elelyso, which is marketed in collaboration with Pfizer. The company also explores additional revenue streams through licensing agreements for its technologies and products, potential royalties from partners, and government grants for research and development. Key partnerships, such as those with Pfizer for distribution and marketing, significantly contribute to its earnings, while ongoing clinical trials and product development efforts aim to expand its portfolio and market presence.

Protalix Financial Statement Overview

Summary

Protalix has shown significant improvement in profitability and cash flow generation, crucial for financial stability. While leverage remains a concern, the positive momentum in financial health is evident. Continued focus on revenue growth and debt reduction is vital.

Income Statement

The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.

Balance Sheet

Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.

Cash Flow

The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.95M	53.40M	65.49M	47.64M	38.35M	62.90M
Gross Profit	35.64M	29.08M	42.51M	28.05M	22.00M	52.02M
EBITDA	10.55M	6.52M	12.94M	-10.78M	-18.94M	4.45M
Net Income	6.28M	2.93M	8.31M	-14.93M	-27.58M	-6.52M
Balance Sheet
Total Assets	78.49M	73.42M	84.43M	55.79M	73.67M	67.93M
Cash, Cash Equivalents and Short-Term Investments	33.40M	34.83M	44.56M	22.18M	38.98M	38.55M
Total Debt	5.35M	5.53M	26.28M	33.47M	33.47M	64.40M
Total Liabilities	28.58M	30.21M	50.87M	66.43M	79.70M	94.97M
Stockholders Equity	49.90M	43.21M	33.57M	-10.64M	-6.04M	-27.04M
Cash Flow
Free Cash Flow	-3.44M	7.39M	-2.47M	-25.63M	-11.74M	-26.76M
Operating Cash Flow	-2.19M	8.67M	-1.32M	-25.00M	-10.29M	-26.11M
Investing Cash Flow	4.26M	4.22M	-16.71M	-5.04M	18.92M	-19.95M
Financing Cash Flow	-7.61M	-16.79M	24.67M	8.24M	12.08M	46.47M

Protalix Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Neutral. The current price of 2.19 is below the 20-day moving average (MA) of 2.30, above the 50-day MA of 2.12, and above the 200-day MA of 2.04, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 46.92 is Neutral, neither overbought nor oversold. The STOCH value of 37.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLX.

Protalix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	69 Neutral	$174.61M	29.59	15.99%	―	62.79%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CHRS	46 Neutral	$161.97M	―	-860.65%	―	-72.54%	-19972.15%
IPHA	46 Neutral	$162.51M	―	-271.32%	―	-75.77%	-31.24%
SLS	43 Neutral	$198.87M	―	-180.71%	―	―	64.43%
TARA	39 Underperform	$165.52M	―	-43.02%	―	―	48.80%
FBRX	36 Underperform	$135.64M	-1.37	-73.46%	―	―	62.69%

Protalix Corporate Events

Protalix Faces EMA Setback on Elfabrio® Dosing

On October 17, 2025, Protalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion on the proposed dosing regimen for Elfabrio®. This decision may impact the company’s market strategy and regulatory approach for Elfabrio® in Europe, potentially affecting stakeholders and future commercial plans.

The most recent analyst rating on (PLX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Protalix BioTherapeutics Reports Robust Growth Amid Challenges

Protalix BioTherapeutics’ recent earnings call painted a picture of robust growth and promising developments, despite some challenges. The company reported significant revenue increases and advancements in their product pipeline, particularly with Elfabrio and PRX-115. While there were concerns about decreased sales in certain regions and rising expenses, the overall sentiment remained positive, buoyed by strong partnerships and market potential.

Protalix Amends Market Offering Agreement with H.C. Wainwright

On August 22, 2025, Protalix BioTherapeutics, Inc. amended its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell shares of its common stock through an equity offering program. This amendment aligns with the company’s new registration statement, potentially impacting its market operations and stakeholder interests.

The most recent analyst rating on (PLX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.

Protalix BioTherapeutics Reports Strong Q2 2025 Results

Protalix BioTherapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company operates within the pharmaceutical industry and is notable for being the first to receive FDA approval for a protein produced through a plant cell-based system.

Protalix Lawsuit Dismissed After Bylaws Amendment

On August 1, 2025, Protalix BioTherapeutics, Inc. announced the dismissal of a class action lawsuit filed by Kevin Mathew Thomas against the company and its Board of Directors. The lawsuit, filed on March 10, 2025, alleged violations in the company’s bylaws. The company denied all allegations but amended the bylaws on May 8, 2025, leading to the plaintiff agreeing that the claims were moot. Consequently, the company agreed to pay $160,000 in fees and expenses to the plaintiff’s counsel, and the case was dismissed with prejudice on July 23, 2025.

The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.